Oncothyreon announces appointments to board of directors

About this update from Cascade Copper Corp.

[{"type":"text","content":"\n\n\n\nBELLEVUE, WA, June 9 /CNW/ - Oncothyreon Inc. (Nasdaq: ONTY) (TSX: ONY)\n(the "Company") today announced that Daniel K. Spiegelman and Stephen K.\nBurley, M.D., D.Phil. have joined its board of directors for three-year terms.\nThe Company also announced the retirement of S. Robert Blair from the board of\ndirectors.\n\n\nMr. Spiegelman is Senior Vice President and Chief Financial Officer at CV\nTherapeutics in Palo Alto, California. He will assume the chairmanship of the\naudit committee at Oncothyreon on July 1, 2008. Dr. Burley is Chief Scientific\nOfficer and Senior Vice President at SGX Pharmaceuticals, Inc., and Adjunct\nProfessor at both the Rockefeller University and the University of California\nin San Diego.\n\n\n"We are very pleased that Dan Spiegelman and Stephen Burley will be\nbringing their financial and scientific expertise and leadership to our board\nof directors," said Christopher S. Henney, Ph.D., Chairman of the board of\ndirectors at Oncothyreon. "We are also grateful for the many years of service\nwhich Bob Blair has given to this Company."\n\n\nAbout Oncothyreon\n\n\nOncothyreon is a biotechnology company specializing in the development of\ninnovative therapeutic products for the treatment of cancer. Oncothyreon's\ngoal is to develop and commercialize novel synthetic vaccines and targeted\nsmall molecules that have the potential to improve the lives and outcomes of\ncancer patients. For more information visit www.oncothyreon.com.\n\n\nAdditional Information\n\n\nAdditional information relating to Oncothyreon can be found on U.S. EDGAR\nat www.sec.gov and on SEDAR at www.sedar.com.\n\n\n","length":1723,"tagName":"div"}]

More updates from Cascade Copper Corp.